RQ Biotechnology Ltd was launched in the UK on 17 May to develop broad-spectrum monoclonal antibodies to protect vulnerable people at risk of severe disease from existing, emerging and new viral infections. The company’s scientific co-founders are the University of Oxford and the UK medical research charity LifeArc, formerly MRC Technology. RQ Biotechnology is initially being financed under a licensing agreement with AstraZeneca Plc for candidate antibody drugs to treat SARS-CoV-2 infections.
